Atrium Therapeutics, Inc. Common Stock Free Cash Flow Generation Index
Atrium Therapeutics, Inc. Common Stock free cash flow generation index. Atrium Therapeutics, Inc. Common Stock (RNA) has a Free Cash Flow Generation Index of 0.95x as of December 2023. Free cash flow of $15.64 Million represents 1% of operating cash flow ($16.50 Million).
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Free Cash Flow Generation Index of Atrium Therapeutics, Inc. Common Stock (2019–2019)
Free cash flow generation index of Atrium Therapeutics, Inc. Common Stock from 2019 to 2019. Historical FCF Generation Index trend for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. See Atrium Therapeutics, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Atrium Therapeutics, Inc. Common Stock Free Cash Flow Generation Index by Year (2019–2019)
Atrium Therapeutics, Inc. Common Stock free cash flow generation index by year from 2019 to 2019. Year-by-year Free Cash Flow Generation Index for Atrium Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see RNA cash flow conversion.
| Year | FCG Index | Free Cash Flow (USD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.91x | $2.25 Million | $2.49 Million | $235.00K | — |